Full metadata record
|dc.identifier.citation||VOL 39, NO 1-385||-|
|dc.description.abstract||Serine/threonine kinases (STKs) represent the majority of discovered kinases to date even though a few Food and Drug Administration approved STKs inhibitors are reported. The third millennium came with the discovery of an important group of STKs that reshaped our understanding of several biological signaling pathways. This family was named death-associated protein kinase family (DAPK family). DAPKs comprise five members (DAPK1, DAPK2, DAPK3, DRAK1, and DRAK2) and belong to the calcium/calmodulindependent kinases domain. As time goes on, the list of biological functions of this family is constantly updated. The most extensively studied member is DAPK1 (based on the publications number and Protein Data Bank reported crystal structures) that plays||-|
|dc.publisher||Medicinal research reviews||-|
|dc.title||Death-associated protein kinase (DAPK) family modulators: Current and future therapeutic outcomes||-|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.